Century Therapeutics Inc (IPSC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.11+0.96%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IPSC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -86.1% |
| Our one-year growth estimate | diamond | -92.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 6.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IPSC — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition On August 12, 2026, Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securiti…
Why it matters: New data could strengthen the case for CNTY-813 as a functional cure for type 1 diabetes.
Supportive ifGood early data at EASD 2026 show that CNTY-813 could be promising.
Worry ifData from EASD 2026 show no major progress for CNTY-813.
Why it matters: Initial clinical data will show how well CNTY-813 works for type 1 diabetes.
Supportive ifInitial clinical data from CNTY-813 is reported in 2H 2027.
Worry ifInitial clinical data will not be reported until the second half of 2027.
Why it matters: Keeping or increasing revenue is key for investor trust. Stagnation may worry about the company's growth.
Worry ifRevenue exceeds $109M in the next quarter.
Less concerning ifRevenue remains at or below $109M for consecutive quarters.
Why it matters: The ADA presentation may show CNTY-813's potential and draw attention. Good feedback may help the therapy's trust.
Supportive ifThe ADA presentation on June 8, 2026, gets positive feedback.
Worry ifThere was negative feedback about CNTY-813 at the ADA presentation. People showed no interest.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$245 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $770 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,698 loss on $10,000 · 37.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The IND submission is important for CNTY-813. It may cure type 1 diabetes. A successful submission shows progress in clinical development.
Supportive ifCNTY-813 IND submission occurs as planned in 4Q 2026.
Worry ifIND submission is delayed beyond 4Q 2026.
Why it matters: Starting the CNTY-308 trial is important for Century's cancer therapies. It shows they are moving forward.
Supportive ifCNTY-308 clinical trial begins as planned in 2026.
Worry ifCNTY-308 trial initiation is delayed beyond 2026.